CD262 antibodies, human

CD262 antibodies, human

Clone: DJR2-4 | Dilution: 1:11
The DJR2-4 antibody binds to death receptor 5 (DR5), member 10B of the TNF receptor superfamily (TNFRSF10B), also known as CD262, TRAIL-R2/ TRAILR2, TRICK2, KILLER, and ZTNFR9. Binding of TNF-related apoptosis-inducing ligand (TRAIL, TNFSF10, TL2, APO2L, Apo-2L) to DR5 induces apoptosis via the intracellular adaptor molecule FADD/MORT. The DR5 receptor is broadly expressed on many tumors and normal tissues. DR5 expression is upregulated by interferon α, taxotere, and paclitaxel, making DR5
+
target cells more susceptible to NK cell mediated killing.

Alternative names

TNFRSF10B, DR5, KILLER, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9

Technical specifications

  • Antigen: CD262
  • Clone: DJR2-4
  • Isotype: mouse IgG1κ
  • Isotype control: Mouse IgG1 – isotype control antibodies
  • Alternative names of antigen: TNFRSF10B, DR5, KILLER, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9
  • Entrez Gene ID: 8795
  • Molecular mass of antigen [kDa]: 42
  • Distribution of antigen: heart, leukocytes, liver, lung, ovary, pancreas, placenta, spleen, thymocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Fixation: The antibody is suited for staining of formaldehyde-fixed cells.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: APC, Biotin
  • Selected references

    1. Sato, K. et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J. Immunol. 174(7): 4025-4033
    2. Uno, K. et al. (2003) TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101(9): 3658-3667
    3. Walczak, H. et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16(17): 5386-5397
    4. LaVallee, T. M. et al. (2003) 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63(2): 468-475
    5. Nimmanapalli, R. et al. (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 62(2): 759-763
    6. Qiu, Y. et al. (2007) The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 67(10): 4973-4980
    7. Cheent, K. and Khakoo, S. I. (2011) Natural killer cells and hepatitis C: action and reaction. Gut 60(2): 268-278
    8. MacFarlane, M. et al. (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272(41): 25417-25420
    9. Gajate, C. and Mollinedo, F. (2005) Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem. 280(12): 11641-11647
    10. Stolfi, C. et al. (2011) 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol. Cancer Ther. 10(10): 1969-1981
    11. Shigeno, M. et al. (2003) Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene 22(11): 1653-1662
Product options: 3
130-097-260

CD262-PE, human

for 100
tests
(1)
EUR 265,00 
130-097-249

CD262-APC, human

for 100
tests
(1)
EUR 265,00 
130-097-303

CD262-Biotin, human

for 100
tests
(1)
EUR 220,00